hair-bulb
发表于 2025-3-25 04:44:39
http://reply.papertrans.cn/71/7053/705205/705205_21.png
通知
发表于 2025-3-25 08:00:22
collaborative groups such as the GINECO group in France and theirintegration in wider clinical research networks at the European (ENGOT) andinternational (GCIG) level..978-3-319-81199-4978-3-319-32110-3
增强
发表于 2025-3-25 13:21:40
http://reply.papertrans.cn/71/7053/705205/705205_23.png
evaculate
发表于 2025-3-25 18:15:02
http://reply.papertrans.cn/71/7053/705205/705205_24.png
闪光你我
发表于 2025-3-25 22:22:06
http://reply.papertrans.cn/71/7053/705205/705205_25.png
宽大
发表于 2025-3-26 01:40:46
http://reply.papertrans.cn/71/7053/705205/705205_26.png
屈尊
发表于 2025-3-26 06:40:40
Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary or Peritoneummotherapy, hormonal therapy, and targeted agents such as bevacizumab. MEK inhibitor therapy has had promising activity in a phase II trial, and multiple phase III trials of MEK inhibitor therapy for recurrent low-grade serous carcinoma are ongoing.
难解
发表于 2025-3-26 08:48:46
http://reply.papertrans.cn/71/7053/705205/705205_28.png
圣歌
发表于 2025-3-26 14:51:38
http://reply.papertrans.cn/71/7053/705205/705205_29.png
Cupping
发表于 2025-3-26 17:20:30
http://reply.papertrans.cn/71/7053/705205/705205_30.png